Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.

• Status: Completed
• Trial end date: 2014-09-09
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to assess the pharmacokinetics (PK), metabolism, routes and extent of elimination, safety and tolerability of a single oral dose of [14C] BMS-955176 in healthy male subjects. There is no formal research hypothesis to be statistically tested for this study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb; ViiV Healthcare
• Collaborator: GlaxoSmithKline
• Treatments: BMS-955176

Criteria

Inclusion Criteria:

• Healthy Male subjects

• Ages 18-50 years

• Body weight of at least 110 lbs (50kg)

• BMI of 18 to 32 kg/m^2

• non-smoking

Exclusion Criteria:

• Clinically significant diagnostic or therapeutic radiation exposure within the previous 12 months (eg serial X-ray or CAT scans, barium meals).

• gastrointestinal disease including gastrointestinal surgery

• constipation or irregular bowel movements